Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection
- PMID: 2465735
- DOI: 10.1016/0166-3542(88)90032-0
Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection
Erratum in
- Antiviral Res 1989 May-Jun;11(4):215
Abstract
R-837, a compound with no in vitro anti-HSV activity, was administered intravaginally to guinea pigs (5 mg/kg every 12 h) for five days beginning 12 h after genital HSV-2 inoculation. Drug treatment reduced vaginal viral replication (P less than 0.0001), completely protected against primary disease and reduced recurrent genital HSV disease (P less than 0.0001). Drug treatment also induced mild fever, weight loss, and decreased water intake. R-837 was a potent interferon inducer, which also induced variable enhancement of cell-mediated cytolytic activity against HSV-2 targets. Less than 36 h of vaginal HSV shedding was observed in animals with R-837 induced early enhancement of HSV-target cytolysis. Compared to placebo, R-837 decreased ELISA and ADCC antibody to HSV-2, but accelerated HSV-2 specific in vitro IL-2 production and peripheral blood mononuclear cell (PBMC) proliferation. R-837 exhibited potent anti-HSV activity in vivo apparently due to cytokine induction and enhancement of cell-mediated responses.
Similar articles
-
Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs.Antimicrob Agents Chemother. 1994 Sep;38(9):2059-64. doi: 10.1128/AAC.38.9.2059. Antimicrob Agents Chemother. 1994. PMID: 7811019 Free PMC article.
-
Effects of cytokines and R-837, a cytokine inducer, on UV-irradiation augmented recurrent genital herpes in guinea pigs.Antiviral Res. 1991 May;15(4):315-22. doi: 10.1016/0166-3542(91)90012-g. Antiviral Res. 1991. PMID: 1659313
-
Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine.Vaccine. 2001 Feb 8;19(13-14):1820-6. doi: 10.1016/s0264-410x(00)00387-x. Vaccine. 2001. PMID: 11166907
-
Immunomodulation as a treatment strategy for genital herpes: review of the evidence.Int Immunopharmacol. 2002 Mar;2(4):443-51. doi: 10.1016/s1567-5769(01)00184-9. Int Immunopharmacol. 2002. PMID: 11962724 Review.
-
Current thinking on genital herpes.Curr Opin Infect Dis. 2014 Feb;27(1):75-83. doi: 10.1097/QCO.0000000000000029. Curr Opin Infect Dis. 2014. PMID: 24335720 Review.
Cited by
-
Clearance of infection with Mycobacterium bovis BCG in mice is enhanced by treatment with S28463 (R-848), and its efficiency depends on expression of wild-type Nramp1 (resistance allele).Antimicrob Agents Chemother. 2001 Nov;45(11):3059-64. doi: 10.1128/AAC.45.11.3059-3064.2001. Antimicrob Agents Chemother. 2001. PMID: 11600356 Free PMC article.
-
TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines.Cancer Immunol Immunother. 2007 Aug;56(8):1133-41. doi: 10.1007/s00262-006-0262-3. Epub 2006 Dec 1. Cancer Immunol Immunother. 2007. PMID: 17139492 Free PMC article.
-
Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways.Mol Cell Biol. 1995 Apr;15(4):2207-18. doi: 10.1128/MCB.15.4.2207. Mol Cell Biol. 1995. PMID: 7534379 Free PMC article.
-
Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.Blood. 2010 Mar 11;115(10):1949-57. doi: 10.1182/blood-2009-08-238543. Epub 2010 Jan 11. Blood. 2010. PMID: 20065291 Free PMC article.
-
Topical Treatment of Melanoma In Situ, Lentigo Maligna, and Lentigo Maligna Melanoma with Imiquimod Cream: A Systematic Review of the Literature.Dermatol Ther (Heidelb). 2023 Oct;13(10):2187-2215. doi: 10.1007/s13555-023-00993-1. Epub 2023 Aug 24. Dermatol Ther (Heidelb). 2023. PMID: 37615838 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical